Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry

Abstract

Introduction: Phase III clinical trials of dexamethasone intravitreal implant for diabetic macular oedema (DMO) have reported significant improvements in visual acuity (VA). Studies evaluating the treatment of DMO in routine clinical practice provide data to identify areas that need improvement. This study evaluated 12-month treatment outcomes of dexamethasone implant for DMO in routine clinical practice. Methods: Retrospective data analysis of eyes that started dexamethasone implant for DMO from 1 June 2013 to 30 April 2019 in routine clinical practice tracked in the Fight Retinal Blindness! Registry.

Treatment of Diabetic Macular Edema or Macular Edema Following Retinal Vein Occlusion Based on Repeated Injection of the Dexamethasone Intravitreal Implant: A Retrospective Real-World Analysis

“…These improvements align with those observed in other recent real-world studies. [12][13][14][15][16][17] For both outcome measures, peak effectiveness was observed at 6 weeks post-treatment. This is a little earlier than in other analyses, which typically found that the effects of DEX on VA and CMT peaked at 2-3 months.…”

“…Several previous studies found that VA improvements with DEX were greater in patients who were previously treatment-naïve. 10 , 12 , 13 , 15 , 16 On the flipside, a recent analysis of data from an international registry found no effect of prior treatment on VA improvements following DEX injection in 204 patients with DMO; 17 however, the comparison was made at 12 months, which is later than other studies (assessing VA at 1–6 months post-treatment), potentially masking short-term effects.…”

“…Importantly, the efficacy and safety of DEX must be evaluated not just in clinical trials but also in the context of routine clinical practice. Increasing numbers of studies are now collecting "real-world data" across the globe, [9][10][11][12][13][14][15][16][17] but few such analyses have been performed in the United Kingdom. Furthermore, there are many important clinical questions that remain to be adequately addressed.…”

Therapeutic Investigation of Palm Oil Mill Effluent-Derived Beta-Carotene in Streptozotocin-Induced Diabetic Retinopathy via the Regulation of Blood–Retina Barrier Functions

“…Experimentally, synthetic glucocorticoid, i.e., DEX, is used for the treatment of DR due to its anti-inflammatory and immunological defensive properties [ 69 , 70 ]. PBC also possesses multi-targeted actions, such as DEX, and it protects from cellular oxidative damage in multiple diabetic complications [ 71 , 72 ].…”

Astaxanthin Ameliorates Diabetic Retinopathy in Swiss Albino Mice via Inhibitory Processes of Neuron-Specific Enolase Activity

“…The natural astaxanthin has favorable effects against ischemia-reperfusion injury associated with brain damage and neurovascular inflammation [64]. Commercially, the synthetic glucocorticoid, i.e., DEX, is widely used in various inflammatory and immunological disorders including DR [65,66]. AST possesses multi-targeted actions similar to dexamethasone and it protects the retinal blood vessels in diabetic conditions [67].…”